KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Esperion Therapeutics (ESPR) EBIAT (2016 - 2026)

Esperion Therapeutics filings provide 8 years of EBIAT readings, the most recent being $61.8 million for Q4 2025.

  • On a quarterly basis, EBIAT rose 390.04% to $61.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$22.7 million, a 56.17% increase, with the full-year FY2025 number at -$22.7 million, up 56.17% from a year prior.
  • EBIAT hit $61.8 million in Q4 2025 for Esperion Therapeutics, up from -$31.3 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $61.8 million in Q4 2025 to a low of -$90.9 million in Q1 2021.
  • Median EBIAT over the past 5 years was -$52.5 million (2022), compared with a mean of -$39.3 million.
  • The widest YoY moves for EBIAT: up 390.04% in 2025, down 166.3% in 2025.
  • Esperion Therapeutics' EBIAT stood at -$65.1 million in 2021, then grew by 14.79% to -$55.5 million in 2022, then fell by 1.54% to -$56.3 million in 2023, then skyrocketed by 62.16% to -$21.3 million in 2024, then skyrocketed by 390.04% to $61.8 million in 2025.
  • The last three reported values for EBIAT were $61.8 million (Q4 2025), -$31.3 million (Q3 2025), and -$12.7 million (Q2 2025) per Business Quant data.